Sanofi SA

SNY

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Sanofi SA News & Analysis

stocks

10 best US blue-chip stocks to buy for the long term

The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks

10 best US blue-chip shares to buy for the long term

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,570.9030.80-0.36%
CAC 408,154.5131.930.39%
DAX 4022,287.5627.09-0.12%
Dow JONES (US)43,428.02748.63-1.69%
FTSE 1008,659.373.60-0.04%
HKSE23,477.92900.943.99%
NASDAQ19,524.01438.36-2.20%
Nikkei 22538,776.9498.900.26%
NZX 50 Index12,752.58127.78-0.99%
S&P 5006,013.13104.39-1.71%
S&P/ASX 2008,296.2026.60-0.32%
SSE Composite Index3,379.1128.330.85%

Market Movers